Idaho gets $1.3 million from GlaxoSmithKline over drug promotion

newsroom@idahostatesman.comJune 4, 2014 

Pharmaceutical company GlaxoSmithKline will pay Idaho more than $1.3 million as part of a $105 million multistate settlement over allegations that it illegally promoted asthma and depression drugs.

Idaho Attorney General Lawrence Wasden on Wednesday announced the settlement, which included 44 other states.

Idaho accused the company of breaking the Idaho Consumer Protection Act by misrepresenting the uses and qualities of its asthma drug Advair and the antidepressants Paxil and Wellbutrin.

"Idahoans relied on the advertising claims made by this company and expected the company to tell the truth about the proper use and advantages of taking the drug," Wasden said.

GlaxoSmithKline also agreed to change its marketing and promotional practices. Among other things, the company will not make false claims about any of its products, or give samples to doctors who aren't expected to prescribe the drugs for use that is approved by the Food and Drug Administration.

Idaho Statesman is pleased to provide this opportunity to share information, experiences and observations about what's in the news. Some of the comments may be reprinted elsewhere in the site or in the newspaper. We encourage lively, open debate on the issues of the day, and ask that you refrain from profanity, hate speech, personal comments and remarks that are off point. Thank you for taking the time to offer your thoughts.

Commenting FAQs | Terms of Service